BetterLife Pharma (CSE: BETR – OTCQB: BETRF) CEO Ahmad Doroudian joined Steve Darling from Proactive to share news about positive in vitro results of its anti-viral, AP-003’s first proposed target indication is for people at higher risk to develop severe COVID-19 disease.
Doroudian telling Proactive, the early results show the potency rate was similar against a number of variants including Wuhan, Alpha, Beta and South African strains of COVID. Further studies are happening to validate and test AP-003 activity against Gamma, Delta and Lambda variants.